Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates

Bristol-Myers Squibb to Acquire Amylin

Skadden is representing Amylin Pharmaceuticals, Inc. in its $7 billion acquisition by Bristol-Myers Squibb Company, announced on June 29.

BACK TO TOP